Purpose: To evaluate the visual outcome after transitioning from a pro re nata (PRN) intravitreal injection regimen to a treat-and-extend (TAE) regimen for patients with neovascular age-related macular degeneration (AMD). Methods: A retrospective review of patients who were switched from a PRN regimen with intravitreal injections of bevacizumab, ranibizumab or aflibercept to a TAE regimen. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and type of medication used at baseline, at the time of changing treatment regimen and at the end of the study were analysed. Results: Twenty-one eyes of 21 patients met the inclusion criteria. Prior to the switch, the patients received a mean of 13.8 injections (median, 10; range, 3-39 injections) with the PRN regimen for 44 months (range, 3-100 months), which improved the visual acuity in five patients (24%). After a mean of 6.1 injections (median, 5; range, 3-14 injections) with the TAE regimen over 8 months (range, 2-16 months), the visual acuity improved in 12 patients (57%). The improvement in visual acuity during treatment with the TAE regimen was statistically significant (p = 0.005). The proportion of patients with a visual acuity of 0.2 or better was significantly higher after treatment with the TAE regimen than after treatment with the PRN regimen (p = 0.048). No significant differences in CRT were found between the two treatment regimens. Conclusion: Even after prolonged treatment and a high number of intravitreal injections, switching AMD patients from a PRN regimen to a strict TAE regimen significantly improves visual acuity.
Introduction
Neovascular age-related macular degeneration (AMD) is the leading cause of blindness in the Western world, and its prevalence is expected to increase with an ageing population (Pascolini & Mariotti 2012) . Despite the high number of intravitreal injections with bevacizumab (Avastin; Genetech Inc., San Francisco, CA, USA), ranibizumab (Lucentis; Genetech Inc.) and aflibercept (Eylea; Regeneron Inc., Tarrytown, NY, USA) given every year, no international guidelines currently exist on which treatment regimen to follow.
Bevacizumab and ranibizumab have been found to be equally effective in treating neovascular AMD (Martin et al. 2011; Chakravarthy et al. 2013; Kodjikian et al. 2013; Krebs et al. 2013; Berg et al. 2015) . Aflibercept has been shown to be equally as effective as ranibizumab in improving vision for neovascular AMD patients, but with fewer intravitreal injections (Heier et al. 2012; Homer et al. 2015; Panchmatia et al. 2016) . Monthly injections with vascular endothelial growth factor (VEGF) inhibitors have given better results in terms of visual acuity than the pro re nata (PRN) or treatand-observe regimen (Rosenfeld et al. 2006; Brown et al. 2009; Holz et al. 2011; van Asten et al. 2015) . With the PRN regimen, the patients are usually given a loading dose of 3 monthly injections and then followed every 4 weeks receiving an intravitreal injection only when there is evidence of active disease as shown by intraretinal macular oedema and/or subretinal fluid on the optical coherence tomography (OCT) images (Holz et al. 2011) . The treat-and-extend (TAE) regimen, however, has shown visual acuity results that are similar to monthly injections, but with fewer clinic visits (Berg et al. 2015; Hatz & Pr€ unte 2016a) . With the TAE regimen, the patients initially receive 3 monthly injections followed by an intravitreal injection at every visit. The control interval is most commonly prolonged by 2 weeks when no signs of exudation are present and shortened by 2 weeks, to a minimum of 4 weeks, if recurrent disease is detected on the OCT images (Berg et al. 2015) . Changing from bevacizumab or ranibizumab to aflibercept when administered according to a TAE protocol has not been found to cause significant changes in visual acuity (Ferrone et al. 2014; Homer et al. 2015) . There are several adverse events and complications associated with intravitreal injections (Falavarjani & Nguyen 2013) , of which some are clearly correlated to the number of injections while others may be related to the type of medication being injected.
To achieve the best possible visual outcome with the least number of intravitreal injections, all AMD patients at a tertiary referral hospital who were undergoing intravitreal injection treatment for neovascular AMD were routinely transitioned from a PRN regimen to a TAE regimen, regardless of disease activity. To the best of our knowledge, the results of such a change in treatment protocol have previously not been reported. The objectives of this study were to investigate in a real-life setting the changes in BCVA and CRT after switching patients with neovascular AMD from a PRN regimen to a strict TAE regimen.
Materials and Methods
A retrospective chart review was conducted at the Department of Ophthalmology, Lillehammer Hospital, to identify all patients with neovascular AMD who routinely had been transitioned from a PRN regimen to a TAE regimen with bevacizumab, ranibizumab or aflibercept during the time period from December 2013 to April 2015 regardless of whether they had active disease with intraretinal oedema and/or subretinal fluid or not. The patients were identified through a search in the hospital database, using the International Classification of Diseases (ICD) coding system. The study followed the national ethical regulations for clinical research and the Declaration of Helsinki.
All patients who were included in this study had a diagnosis of neovascular AMD. They were switched directly to the TAE regimen without the initial loading dose of three consecutive monthly injections. The control interval was prolonged by 2 weeks when no signs of exudation were present and shortened by 2 weeks, to a minimum of 4 weeks, if recurrent disease was detected by OCT. Further inclusion criteria were a best corrected visual acuity of Snellen 0.1 (logMAR 1.0) or better at the time of the first intravitreal injection (baseline) and at the time of changing the treatment regimen (switch). Eyes with a visual acuity below this level were thought to have more fibrotic or atrophic changes with limited effects of VEGF inhibitors. Patients were also required to have received treatment with at least three injections prior to and three injections after the switch. They were excluded if they did not have a complete record on the dates of visits, best corrected visual acuities, CRT and type of intravitreal injections given. Likewise, patients were excluded if the PRN or TAE regimens were not strictly followed, if they had other eye diseases or systemic conditions that prevented timely injection, or if they were lost to follow-up.
During the chart review, the date, best corrected visual acuity, intraocular pressure, CRT and the type of medication injected were noted for each patient visit. The best corrected visual acuity and CRT at baseline, at the time of the switch and at the end of the study were reviewed and analysed. Three different OCT instruments were used during the study period. The timedomain Stratus OCT 3000 (version 4.0.1, Carl Zeiss Meditec, Dublin, CA, USA) was used until September 2014, when it was changed to the spectral-domain Cirrus HD-OCT 5000 (Carl Zeiss Meditec). Three of the patients had their final CRT measurement done with a Cirrus HD-OCT 4000 at another eye clinic.
The Snellen visual acuity was converted to logMAR values to allow for statistical analysis. The Fisher's exact test was used for categorical variables, and the Wilcoxon signed-rank test was used for continuous variables. The Pearson's correlation was applied to evaluate the correlation between visual acuity and duration of treatment. Twotailed p-values < 0.05 were considered statistically significant. The statistical analyses were performed using IBM SPSS Statistics, version 21 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel 2010 (Microsoft Corp., Redmond, WA, USA).
Results
Our search identified a total of 957 patients with the ICD-10 diagnosis code H35.3 'degeneration of macula and posterior pole', which in addition to different types of AMD includes a number of other maculopathies. Among these patients, 21 eyes of 21 patients (14 female and seven male) with neovascular AMD fulfilled the inclusion criteria of the study. The mean age at initiation of treatment was 71 years (range, 56-93 years). On fluorescein angiography, six patients had a predominantly classic and eight patients had an occult choroidal neovascular membrane. Among the seven patients who did not have a precise description of the neovascular membrane, five showed areas of focal leakage on fluorescein angiography that was not further classified, and for two patients, no detailed information about the results of fluorescein angiography was found.
The patients had received a mean of 13.8 intravitreal injections (median, 10; SD, 10.5; range, 3-39 injections) with bevacizumab, ranibizumab or aflibercept over a mean time period of 44 months (range, 3-100 months), giving an average of one injection every 129 days before the switch from the PRN to the TAE regimen. After the switch, the patients received a mean of 6.1 injections (median, 5; SD, 3.1; range, 3-14 injections) with bevacizumab, ranibizumab or aflibercept over a mean time period of 8 months (range, 2-16 months), giving an average of one injection every 37 days until the end of the study period. These three types of VEGF inhibitors were used throughout the study period, with an increased use of aflibercept after the switch. The mean intraocular pressure measured between the two treatment regimens was 14.9 mm Hg (range, 9-25 mm Hg). The duration of treatment and the type and number of intravitreal injections given prior to and after transitioning to the TAE regimen are given in Table 1 .
During treatment with the PRN regimen, that is the time from onset of the intravitreal injection therapy (baseline) to the switch, the visual acuity increased in five patients (24%), decreased in 14 patients (67%) and remained unchanged in two patients (9%; Fig. 1 ). The change in visual acuity correlated significantly with the duration of treatment (r = À0.70; p < 0.001). During treatment with the TAE regimen, that is the time from the switch to the end of the study, the visual acuity increased in 12 patients (57%), decreased in three patients (14%) and remained unchanged in 6 patients (29%; Fig. 2) . The improvement in visual acuity during treatment with the TAE regimen was statistically significant (p = 0.005). At the last follow-up, 11 of 21 patients (52%) had an improved or stabilized visual acuity in the treated eye compared to baseline (Fig. 3) . The proportion of patients with a visual acuity of 0.2 or better (Snellen) was significantly higher after treatment with the TAE regimen than after treatment with the PRN regimen (p = 0.048). The best corrected visual acuities for all patients at baseline, at the time of the switch and at the end of the study period are presented in Table 2 .
The mean CRT was 311 lm (median, 281 lm; SD, 127.9; range, 164-693 lm) at baseline, 223 lm (median, 207 lm; SD, 124.9; range, 87-579 lm) at the time of the switch and 252 lm (median, 246 lm; SD, 65.2; range, 180-445 lm) at the end of the study. The CRT was significantly reduced during treatment with the PRN regimen (p = 0.002). No significant change in CRT was observed during the subsequent treatment with the TAE regimen (p = 0.26) or from baseline to the end of the study period (p = 0.06). Six of the patients (29%) did not have macular oedema at the time of the switch. At the end of the study period, 13 patients (62%) did not have macular oedema. Eight patients had a stable treatment interval (range, 4-12 weeks), while 10 patients had their treatment interval extended at the last visit. At the end of the study period, the average length of the treatment interval was 7.4 weeks. Table 1 . The duration of treatment and the type and number of intravitreal injections given to each patient (numbered in chronological order according to the date of the first injection) prior to and after transitioning to the treat-and-extend regimen.
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Discussion
The present study shows an improvement in the visual acuity when transitioning patients from a PRN regimen to a strict TAE regimen. This also includes patients who have been treated for a long period of time prior to the start of the TAE regimen. There is currently no clear consensus regarding the optimal treatment regimen for neovascular AMD patients. Recent studies have shown that the TAE regimen results in similar visual acuity outcomes as monthly injections, and that monthly injections and a TAE regimen give better visual acuity than the PRN regimen (Holz et al. 2011; Berg et al. 2015; Hatz & Pr€ unte 2016a) . From this, one can argue that shifting to a TAE regimen may lead to better visual acuity than continuing with a PRN regimen. Most studies have been performed on treatment na€ ıve patients. Recently, however, Hatz & Pr€ unte (2016b) compared the outcomes after switching from a PRN to TAE regimen in patients with active disease and found that this improved the visual acuity and led to fewer patient visits.
What we found particularly interesting in the present study was that the visual acuity improved even after a prolonged treatment period (up to more than 8 years) and a high number of intravitreal injections (up to 39 injections), when switching from a PRN to a TAE regimen. In more than half of the patients, the visual acuity increased during the period of the TAE regimen, and this also included patients without active disease at the time of the switch. A possible explanation for the improvement in visual acuity after changing the treatment protocol is a general undertreatment of the patients on a PRN regimen. The decreased visual acuity during the PRN regimen could be caused by the repeated intraretinal oedema and/or subretinal fluid that develops prior to each intravitreal injection, which may lead to a dysfunction of the retinal cells. Central retinal thickness has been found to be a sensitive and early predictor of deterioration of visual acuity in neovascular AMD patients, and a loss of 4 ETDRS letters or more appears to be associated Fig. 2 . Change in visual acuity (logMAR) during the treat-and-extend regimen of intravitreal vascular endothelial growth factor inhibitor therapy (from the time of the switch to the end of the study). The graph details are the same as described in Fig. 1 . Fig. 3 . Change in visual acuity (logMAR) from baseline to the last follow-up after intravitreal vascular endothelial growth factor inhibitor therapy. The graph details are the same as described in Fig. 1 . with incomplete recovery (Gerding et al. 2011) . This emphasizes the importance of correct patient followup with timely appointments, as demonstrated in the present study. Fourteen of the 21 patients eventually changed medication to aflibercept in order to decrease the number of consultations and intravitreal injections. Such a change in medication has not been shown to improve the visual acuity in previous studies (Heier et al. 2012; Ferrone et al. 2014; Homer et al. 2015) . In eyes with persistent exudation, however, switching treatment from bevacizumab or ranibizumab to aflibercept has been reported to reduce disease activity, but data on the effect on visual acuity of such a conversion to aflibercept are conflicting (Kumar et al. 2013; Eadie et al. 2014) .
No significant differences in CRT were found between the two treatment regimens. This may be due to the use of two different types of OCT systems (time-domain versus spectral-domain) that calculate the CRT differently and therefore are known to give consistently different results (Forooghian et al. 2008; Forte et al. 2009 ). In addition, spectral-domain OCT is more sensitive in detecting subtle macular changes, and thus, we cannot exclude the possibility that the use of different OCT systems may have affected the treatment intervals. Other study limitations include the relatively low number of patients and the retrospective, single-centre design.
The present study, conducted under real-life conditions, indicates that transitioning patients with neovascular AMD from a PRN to a TAE injection regimen significantly improves visual acuity, regardless of disease activity at the time of the switch. Visual recovery was observed even after a prolonged treatment period and a high number of intravitreal injections. Patients who are already on a PRN regimen are likely to benefit from switching to a strict TAE regimen, but larger controlled studies are needed to confirm this.
